Cover Story

Advances in myeloma treatments, diagnostics have specialists ‘talking about cure’

HemOnc Today, November 25, 2018
A decade ago, patients with newly diagnosed multiple myeloma typically survived 3 to 5 years. However, the development of highly effective therapies…
Meeting News

More research needed to realize true benefit of PARP inhibitors in breast cancer

November 8, 2018
NEW YORK — The effectiveness of PARP inhibitors demonstrate a proof of principle that targeting DNA repair pathways can be a productive…
Molecular Oncology

New biomarkers and therapeutic target discoveries in molecular oncology

HemOnc Today, November 10, 2018
Wafik S. El-Deiry, MD, PhD, FACP
A number of significant advances in molecular oncology have come to light in recent weeks, providing new knowledge for understanding immunotherapy…
Meeting News

Immune-related adverse events manageable with vigilance, appropriate treatment

November 8, 2018
NEW YORK — Advances in immunotherapy have transformed cancer treatment but require clinicians to be vigilant for adverse events, according to a…
Meeting News

Sarcoma treatments evolve as understanding of disease biology improves

November 7, 2018
NEW YORK — The treatment landscape in sarcoma is evolving rapidly as the research community recognizes the importance of matching therapies to…
Meeting News

Efficacy, safety must guide treatment sequencing decisions in chronic myeloid leukemia

November 7, 2018
NEW YORK — The approval of multiple tyrosine kinase inhibitors for chronic myeloid leukemia has greatly expanded the therapeutic armamentarium…
Meeting News

Second-line therapy for myelofibrosis remains ‘active area of research’

November 7, 2018
NEW YORK — Ruxolitinib has dramatically improved the care of patients with myelofibrosis, but new treatment strategies for patients who…
Feature

Removal of ‘cancer’ label could reduce overdiagnosis, overtreatment of low-risk disease

October 26, 2018
Use of the term “cancer” at diagnosis may prompt individuals with low-risk lesions to choose aggressive treatment that could do more harm…
Advanced Practice

APPs should encourage utilization of tumor treating fields for glioblastoma

HemOnc Today, October 25, 2018
David L. Jennings II, MSN, RN, AGPCNP-BC
Advancements in the field of neuro-oncology seem to occur all too infrequently. Perhaps the most significant contributing factor to this is the…
Commentary

TAILORx ‘shows path’ to de-escalate therapy for some women, raises treatment questions for others

HemOnc Today, October 25, 2018
Douglas Yee, MD
Adjuvant therapy of breast cancer has unquestionably resulted in improved survival for women with operable breast cancer. NSABP B-20 —…